Trial Profile
An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2019
Price :
$35
*
At a glance
- Drugs Beraprost (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Lung Biotechnology
- 17 Jun 2014 New trial record